Immunology and Oncology Unit, Newcastle, New South Wales, Australia.
Clin Cancer Res. 2011 Feb 15;17(4):721-30. doi: 10.1158/1078-0432.CCR-10-2225. Epub 2010 Nov 18.
To examine mechanisms that determine long-term responses of B-RAF(V600E) melanoma cells to B-RAF inhibitors.
B-RAF(V600E) melanoma cells were exposed to the B-RAF inhibitor PLX4720 for prolonged periods to select for cells resistant to apoptosis induced by the inhibitor. The resultant cells were analyzed for activation of extracellular signal regulated kinase (ERK), MAP/ERK kinase (MEK), and Akt, and related signals. Their roles in survival of the cells were also examined.
B-RAF(V600E) melanoma cells selected for resistant to PLX4720-induced apoptosis retained the V600E mutation in B-RAF, and proliferated steadily in the presence of the inhibitor, albeit with slow growth rate. These cells displayed high levels of ERK activation, that is, at least in part, independent of the conventional RAF/MEK/ERK pathway, as MEK activation was low and inhibition of MEK did not significantly block activation of ERK. In contrast, extracellular signals appeared involved. This was associated with elevated activation of the phosphoinositide 3-kinase (PI3k)/Akt pathway and could be inhibited by serum starvation and inhibition of PI3k/Akt. Inhibition of MEK did not impact on survival of these cells, whereas serum starvation, inhibition of PI3K/Akt, and inhibition of ERK1/2 reduced their viability.
These results indicate that sensitivity to induction of apoptosis may be a major determinant of long-term responses of B-RAF(V600E) melanomas to specific inhibitors and suggest that rebound melanoma growth after initial treatment with the inhibitors may not be responsive to MEK inhibitors, but may be susceptible to inhibition of the PI3k/Akt pathway.
研究决定 B-RAF(V600E) 黑色素瘤细胞对 B-RAF 抑制剂长期反应的机制。
将 B-RAF(V600E) 黑色素瘤细胞长时间暴露于 B-RAF 抑制剂 PLX4720 中,以选择对抑制剂诱导的细胞凋亡有抗性的细胞。分析所得细胞中细胞外信号调节激酶 (ERK)、MAP/ERK 激酶 (MEK) 和 Akt 的激活情况及其相关信号。还研究了它们在细胞存活中的作用。
选择对 PLX4720 诱导的细胞凋亡具有抗性的 B-RAF(V600E) 黑色素瘤细胞保留了 B-RAF 的 V600E 突变,并且尽管生长速度缓慢,但在抑制剂存在下仍稳定增殖。这些细胞表现出高水平的 ERK 激活,即至少部分独立于传统的 RAF/MEK/ERK 途径,因为 MEK 激活较低,抑制 MEK 并不能显著阻断 ERK 的激活。相比之下,细胞外信号似乎参与其中。这与磷酸肌醇 3-激酶 (PI3k)/Akt 途径的激活升高有关,可通过血清饥饿和 PI3k/Akt 抑制来抑制。抑制 MEK 对这些细胞的存活没有影响,而血清饥饿、PI3K/Akt 抑制和 ERK1/2 抑制降低了它们的活力。
这些结果表明,对凋亡诱导的敏感性可能是 B-RAF(V600E) 黑色素瘤对特定抑制剂的长期反应的主要决定因素,并表明抑制剂初始治疗后黑色素瘤的反弹生长可能对 MEK 抑制剂无反应,但可能对 PI3k/Akt 途径的抑制敏感。